Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tobemstomig + axitinib
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Tobemstomig + axitinib** is a combination therapy consisting of tobemstomig, a bispecific antibody targeting both PD-1 and TIM-3, and axitinib, a small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1–3. Tobemstomig is designed to block immune checkpoint pathways, enhancing T-cell mediated anti-tumor immunity. Axitinib inhibits angiogenesis by selectively blocking VEGFR-1, VEGFR-2, and VEGFR-3, thereby reducing tumor blood supply and promoting tumor cell apoptosis. The combination aims to leverage immune system activation (through checkpoint inhibition) in synergy with angiogenesis inhibition, primarily for the treatment of advanced or metastatic renal cell carcinoma and potentially other solid tumors.
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on tobemstomig + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tobemstomig + axitinib.